CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today reported financial results for the fourth quarter and year-ended December 31, 2014.
“2014 was a defining year for BIND as we made considerable progress in transitioning the company from a platform technology to a drug development company,” said Andrew Hirsch, BIND’s newly appointed acting president and chief executive officer.
Help employers find you! Check out all the jobs and post your resume.
